A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

NCT06045221 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication orforglipron (LY3502970) against semaglutide in adults with type 2 diabetes whose blood sugar levels are not well controlled with metformin alone.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 1,698 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-09 · est. completion 2025-08

Where 131 sites · Argentina, China, Japan, Mexico, Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT06045221 ↗

Description as written by the study sponsor.

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally
Semaglutide Drug

Administered orally

Main thing measured	Change from Baseline in Hemoglobin A1c (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes
GLP-1 drugs	semaglutide, orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06045221 ↗